Slifka MK - Search Results

1

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection.

Ricciardi MJ, Rust LN, Pedreño-Lopez N, Yusova S, Biswas S, Webb GM, Gonzalez-Nieto L, Voigt TB, Louw JJ, Laurino FD, DiBello JR, Raué HP, Barber-Axthelm AM, Chun K, Uttke S, Raphael LMS, Yrizarry-Medina A, Rosen BC, Agnor R, Gao L, Labriola C, Axthelm M, Smedley J, Julander JG, Bonaldo MC, Walker LM, Messaoudi I, Slifka MK, Burton DR, Kallas EG, Sacha JB, Watkins DI, Burwitz BJ. Ricciardi MJ, et al. Among authors: slifka mk. Sci Transl Med. 2023 Mar 29;15(689):eade5795. doi: 10.1126/scitranslmed.ade5795. Epub 2023 Mar 29. Sci Transl Med. 2023. PMID: 36989376 Free PMC article.

2

Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.

Slifka MK, Shen H, Matloubian M, Jensen ER, Miller JF, Ahmed R. Slifka MK, et al. J Virol. 1996 May;70(5):2902-10. doi: 10.1128/JVI.70.5.2902-2910.1996. J Virol. 1996. PMID: 8627765 Free PMC article.

3

Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity.

Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Shen H, et al. Among authors: slifka mk. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3987-91. doi: 10.1073/pnas.92.9.3987. Proc Natl Acad Sci U S A. 1995. PMID: 7732018 Free PMC article.

4

Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG.

Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ. Slifka MK, et al. Transplantation. 2013 May 15;95(9):e59-61. doi: 10.1097/TP.0b013e31828c6d9e. Transplantation. 2013. PMID: 23648410 Free PMC article. No abstract available.

5

Limiting dilution analysis of virus-specific memory B cells by an ELISPOT assay.

Slifka MK, Ahmed R. Slifka MK, et al. J Immunol Methods. 1996 Nov 29;199(1):37-46. doi: 10.1016/s0022-1759(96)00146-9. J Immunol Methods. 1996. PMID: 8960096

6

Long-term antibody production is sustained by antibody-secreting cells in the bone marrow following acute viral infection.

Slifka MK, Ahmed R. Slifka MK, et al. Ann N Y Acad Sci. 1996 Oct 25;797:166-76. doi: 10.1111/j.1749-6632.1996.tb52958.x. Ann N Y Acad Sci. 1996. PMID: 8993360

7

GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination.

Judkowski V, Bunying A, Ge F, Appel JR, Law K, Sharma A, Raja-Gabaglia C, Norori P, Santos RG, Giulianotti MA, Slifka MK, Douek DC, Graham BS, Pinilla C. Judkowski V, et al. Among authors: slifka mk. PLoS One. 2011;6(9):e24091. doi: 10.1371/journal.pone.0024091. Epub 2011 Sep 9. PLoS One. 2011. PMID: 21931646 Free PMC article.

8

Noncytolytic HIV immunity.

Slifka MK. Slifka MK. Trends Microbiol. 1999 Apr;7(4):143. doi: 10.1016/s0966-842x(99)01488-2. Trends Microbiol. 1999. PMID: 10219049 No abstract available.

9

CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection.

Whitmire JK, Slifka MK, Grewal IS, Flavell RA, Ahmed R. Whitmire JK, et al. Among authors: slifka mk. J Virol. 1996 Dec;70(12):8375-81. doi: 10.1128/JVI.70.12.8375-8381.1996. J Virol. 1996. PMID: 8970958 Free PMC article.

10

HCV-specific immunosuppression.

Slifka M. Slifka M. Trends Microbiol. 2001 Jul;9(7):311. doi: 10.1016/s0966-842x(01)02110-2. Trends Microbiol. 2001. PMID: 11435088 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page